A pharmaceutical composition for treating vomiting

A composition and drug technology, applied in the field of medicine, can solve the problems of delayed or early vomiting that are not particularly effective and cannot prevent nausea and vomiting of patients

Inactive Publication Date: 2017-10-24
HAISCO PHARMA GRP INC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been clinically proven that the antiemetic properties of 5-HT3 receptor antagonists have greatly improved the nausea and vomiting associated with cancer chemotherapy, but 5-HT3 receptor antagonists cannot prevent nausea and vomiting in all patients, and have no effect on delayed or early vomiting not particularly effective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A pharmaceutical composition for treating vomiting
  • A pharmaceutical composition for treating vomiting
  • A pharmaceutical composition for treating vomiting

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1: Aprepitant / Palonosetron Hydrochloride / Dexamethasone Granules

[0013] The prescription is as follows, all of which are the weight composition of the unit preparation:

[0014]

[0015] The preparation method is as follows:

[0016] Pass aprepitant, palonosetron hydrochloride, dexamethasone, lactose, croscarmellose sodium, aspartame, and povidone K30 through an 80-mesh sieve, and then weigh them according to the prescription amount The amount of 1000 unit preparations, mix thoroughly and evenly. Add 40ml of water, adjust the stirring rate of the wet mixing granulator to 160 rpm, the shear rate to 2000 rpm, granulate for 10 minutes, pass through a 16-mesh sieve, dry at 70°C and granulate with a 14-mesh sieve to obtain .

Embodiment 2

[0017] Embodiment 2: Aprepitant / palonosetron hydrochloride / dexamethasone dispersible tablet

[0018] The prescription is as follows, all of which are the weight composition of the unit preparation:

[0019]

[0020]

[0021] The preparation method is as follows:

[0022] Weigh aprepitant, palonosetron hydrochloride, and dexamethasone according to the prescription amount, use microcrystalline cellulose as filler, cross-linked carmellose sodium, polyvinylpyrrolidone as disintegrant, 5% PVP The 60% alcohol solution is used as the binder, and the micropowdered silica gel is used as the flow aid. It is granulated in one step in a fluidized bed, and then compressed into tablets.

Embodiment 3

[0023] Embodiment 3: Aprepitant / palonosetron hydrochloride / dexamethasone capsule

[0024] The prescription is as follows, all of which are the weight composition of the unit preparation:

[0025]

[0026] The preparation method is as follows:

[0027] Aprepitant, panolosetron hydrochloride, dexamethasone, microcrystalline cellulose, and magnesium stearate were respectively passed through a 100-mesh sieve. After weighing according to the prescription amount, put it in a stirring mixer and stir for 15 minutes, fill it into an empty capsule shell, and obtain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
hardnessaaaaaaaaaa
Login to view more

Abstract

The present invention provides a pharmaceutical composition containing neurokinin 1 (NK-1) receptor antagonist, 5-hydroxytryptamine 3 (5HT-3) receptor antagonist and adrenocortical hormone, which is NK-1 receptor antagonist Body antagonists, 5HT-3 receptor antagonists and adrenal cortex hormones are used as active ingredients, some specific types and proportions of auxiliary materials are added, and oral preparations are prepared and developed according to the technical means described in the present invention. The composition can be used for preventing and treating nausea and vomiting caused by cancer radiotherapy, chemotherapy and operation. The object of the present invention is to utilize NK-1 receptor antagonist, 5HT-3 receptor antagonist and adrenocortical hormone to invent a more convenient and effective pharmaceutical composition preparation for preventing and treating vomiting, thereby improving patient compliance.

Description

technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to a pharmaceutical composition containing neurokinin 1 (NK-1) receptor antagonist, 5-hydroxytryptamine 3 (5HT-3) receptor antagonist and adrenocortical hormone. Background technique [0002] Chemotherapy-induced nausea and vomiting (CINV) is very common in clinical practice. If poorly controlled, it will increase the number of visits to the doctor, reduce chemotherapy compliance, reduce the number of chemotherapy times, and even make patients refuse further chemotherapy, etc., seriously affecting the quality of life of patients and resistance to chemotherapy. Tumor treatment effect. Therefore, the prevention and treatment of CINV are very important. CINV is chemotherapy-induced nausea and vomiting. According to the time of vomiting, it is usually divided into 3 categories, acute (occurs within the first 24 hours after the start of chemotherapy), delayed (occurs at leas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/573A61P1/08A61K31/439A61K31/4178A61K31/4184A61K31/46A61K31/473A61K31/438A61K31/496A61K31/5377
Inventor 晏菊芳牟霞李岳
Owner HAISCO PHARMA GRP INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap